TiumBio to Initiate Phase 2 Trial of TU2218 for Cancer
- Written by PR Newswire
 |
- TiumBio will pursue three indications for the TU2218 combination clinical trial with pembrolizumab
- TU2218 demonstrated a favorable safety and a synergetic effect with immuno-oncology drugs in preclinical studies
BOSTON and SEONGNAM, South Korea, March 11, 2024 /PRNewswire/ -- TiumBio Co., Ltd. (KOSDAQ: 321550), a clinical-stage biopharmaceutical...
